Alfano, M.-S.; Garnier, J.; Palen, A.; Ewald, J.; Piana, G.; Poizat, F.; Mitry, E.; Delpero, J.-R.; Turrini, O.
Peak Risk of Recurrence Occurs during the First Two Years after a Pancreatectomy in Patients Receiving Neoadjuvant FOLFIRINOX. Cancers 2023, 15, 5151.
https://doi.org/10.3390/cancers15215151
AMA Style
Alfano M-S, Garnier J, Palen A, Ewald J, Piana G, Poizat F, Mitry E, Delpero J-R, Turrini O.
Peak Risk of Recurrence Occurs during the First Two Years after a Pancreatectomy in Patients Receiving Neoadjuvant FOLFIRINOX. Cancers. 2023; 15(21):5151.
https://doi.org/10.3390/cancers15215151
Chicago/Turabian Style
Alfano, Marie-Sophie, Jonathan Garnier, Anaïs Palen, Jacques Ewald, Gilles Piana, Flora Poizat, Emmanuel Mitry, Jean-Robert Delpero, and Olivier Turrini.
2023. "Peak Risk of Recurrence Occurs during the First Two Years after a Pancreatectomy in Patients Receiving Neoadjuvant FOLFIRINOX" Cancers 15, no. 21: 5151.
https://doi.org/10.3390/cancers15215151
APA Style
Alfano, M. -S., Garnier, J., Palen, A., Ewald, J., Piana, G., Poizat, F., Mitry, E., Delpero, J. -R., & Turrini, O.
(2023). Peak Risk of Recurrence Occurs during the First Two Years after a Pancreatectomy in Patients Receiving Neoadjuvant FOLFIRINOX. Cancers, 15(21), 5151.
https://doi.org/10.3390/cancers15215151
